References
- Bali T, Miller TM. Management of amyotrophic lateral sclerosis. Missouri Medicine. 2013;110:417–21.
- Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330:585–91.
- Fornai F, Longone P, Cafaro L, Kastsiuchenka O, Ferrucci M, Manca ML, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2008;105: 2052–7.
- Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006;441:880–4.
- Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone mediated autophagy. Science. 2004;305:1292–5.
- Bedlack RS, Maragakis N, Heiman-Patterson T. Lithium may slow progression of amyotrophic lateral sclerosis, but further study is needed. Proc Natl Acad Sci U S A. 2008;105: E17, author reply E18.
- Wicks P, Vaughan TE, Massagli MP, Heywood J. Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm. Nat Biotechnol. 2011;29:411–4.
- Gordon PH, Moore DH, Gelinas DF, Qualls C, Meister ME, Werner J, et al. Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology. 2004;62: 1845–7.
- Verstraete E, Veldink JH, Huisman MH, Draak T, Uijtendaal EV, van der Kooi AJ, et al. Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomized sequential trial. J Neurol Neurosurg Psychiatry. 2012; 83:557–64.
- Morrison KE, Dhariwal S, Hornabrook R, Savage L, Burn DJ, Khoo TK, et al. (UKMND-LiCALS Study Group). Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase III multicentre, randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12:339–45.
- Chio A, Borghero G, Calvo A, Capasso M, Caponnetto C, Corbo M, et al. Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial. Neurology. 2010;75:619–25.
- Bruner DW, Hanisch LJ, Reeve BB, Trotti AM, Schrag D, Sit L, et al. Stakeholder perspectives on implementing the National Cancer Institute’s patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Transl Behav Med. 2011;1:110–22.
- Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, et al. Adverse symptom event reporting by patients versus clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101:1624–32.
- Cramon P, Rasmussen AK, Bonnema SJ, Bjorner JB4, Feldt-Rasmussen U2, Groenvold M, et al. Development and implementation of PROgmatic: a clinical trial management system for pragmatic multicentre trials, optimized for electronic data capture and patient reported outcomes. Clinical Trials. 2014;11:344–54.
- Banerjee AK, Okun S, Edwards IR, Wicks P, Smith MY, Mayall SJ, et al. Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER consortium guidance. Drug Saf. 2013;36:1129–49.
- Wicks P, Vaughan T, Heywood J. Subjects no more: what happens when trial participants realize they hold the power? Br Med J. 2014;348: g368. doi: 10.1136/bmj.g368.
- Chalmers I. A guide to patient-led good controlled trials. Lancet. 2000;356:774.